Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond

Expert Rev Clin Pharmacol. 2024 Mar;17(3):235-246. doi: 10.1080/17512433.2024.2310070. Epub 2024 Jan 31.

Abstract

Introduction: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach.

Areas covered: Focusing on pharmacological interventions, we discuss the roles of GLP-1 agonists and GLP/GIP agonists in diabetes management and cardiovascular risk reduction. Tirzepatide, a novel medication, is highlighted for its unique mechanism of action. Clinical trials demonstrate its effectiveness in glucose control, weight reduction, and its potential impact on diabetes, obesity, NASH, and cardiovascular risks.

Expert opinion: Tirzepatide shows promise in diabetes treatment, offering glucose control and weight loss. It also holds potential for addressing comorbidities. However, cautious use is vital due to potential adverse effects and contraindications, including hypersensitivity reactions, pregnancy, and breastfeeding precautions. This review underscores tirzepatide as a valuable addition to diabetes therapies, with evolving prospects for enhanced patient outcomes as research advances.

Keywords: Tirzepatide; diabetes; insulin; review; semaglutide.

Publication types

  • Review

MeSH terms

  • Blood Glucose
  • Diabetes Mellitus* / drug therapy
  • Diabetes Mellitus, Type 2* / drug therapy
  • Female
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide-1 Receptor
  • Glucagon-Like Peptide-2 Receptor*
  • Glycemic Control
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Pregnancy

Substances

  • tirzepatide
  • Blood Glucose
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Glucagon-Like Peptide-2 Receptor